We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Subscribe To Our Newsletter & Stay Updated